摘要
目的:观察葛兰心宁软胶囊对冠心病心绞痛患者血液流变学及免疫炎症因子的影响。方法:120 例冠心病心绞痛患者,依据随机双盲双模拟的原则分为葛兰心宁组和复方丹参组各 60 例,治疗 4 周后进行中医证候疗效及心绞痛疗效评定,并观察治疗前后全血黏度、免疫炎症因子的变化。结果:①葛兰心宁组、复方丹参组中医证候总有效率为分别为83.33%、71.67%,两组疗效差异无统计学意义;葛兰心宁组、复方丹参组心绞痛总有效率分别为81.67%、65.00%,两组比较差异有统计学意义(P<0.05)。②两组全血黏度治疗前后差异有统计学意义(P<0.01,P<0.05);葛兰心宁组治疗后 C 反应蛋白(CRP)及白细胞介素 6(IL 6)均显著降低(P<0.05,P<0.01),而复方丹参组治疗后仅CRP有显著降低(P<0.05)。结论:葛兰心宁改善冠心病心绞痛及其相关症状较复方丹参为优;组分配伍对客观指标(血液流变学、CRP及 IL 6)改善程度要优于饮片层次的配伍。
Objective: To investigate the effect of Gelanxinning soft capsule(GLXN) on the blood-liquid and the immunological inflammatory factor of patients with angina pectoris, contrast to Fufangdanshen tablet(FFDS). Method:According to the principle of, 120 angina pectoris patients were divided randomedly, double blinded and double imitation into two groups(the GLXN group and FFDS group), each group contains 60 patients. The course of treatment for both groups was 4 weeks. Before and after treatment, blood viscosity and the immunological inflammatory factor(CRP and IL-6) were detected respectively; The curative effect of the traditional syndrome and angina pectoris were studied respectively.Result:①The total curative effect of the traditional medical syndrome of GLXN group and FFDS group were 83.33% and 71.67% respectively. Two groups was analyzed by Radit analysis, no significant difference was found between them. The total curative effect of angina pectoris of GLXN group and FFDS group were 81.67% and 65.00% respectively (P< 0.05).②The blood viscosity was decreased significantly than those before treatment(P< 0.01 or P< 0.05) in the two groups. CRP and IL6 were significant decreased (P< 0.01 or P< 0.05) in GLXN group, but only CRP significantly changed in FFDS group(P< 0.05). Conclusion:GLXN could decrease CRP and IL6, so GLXN had the function of protecting vascular endothelium, inhibiting thrombosis and improving artherosclerosis. Available prescription is profitable for the drug effect. GLXN was composed of Radix Puerartae total flavonoid glycosides, Crataegi extract and Jiaogulan total saponins, furthermore it has a understandable mechanism and a suitable target, so it could improve the syndrome and parameters.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2005年第3期141-143,共3页
Journal of Clinical Cardiology
